Pityriasis Rubra Pilaris : A Multicentric Case Series of 65 Spanish Patients
Introduction: PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians. Objective: To add our experience to increase evidence about PRP. Methods: We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being...
| Autores: | , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Fecha de publicación: | 2024 |
| País: | España |
| Institución: | Universidad Francisco de Vitoria |
| Repositorio: | DDFV. Repositorio Institucional de la Universidad Francisco de Vitoria |
| Idioma: | inglés |
| OAI Identifier: | oai:ddfv.ufv.es:10641/7814 |
| Acceso en línea: | https://hdl.handle.net/10641/7814 |
| Access Level: | acceso abierto |
| Palabra clave: | Biologic agents Erythroderma Pityriasis rubra pilaris Pathology and Forensic Medicine Histology Dermatology Multicenter Study Journal Article Yes yes |
| Sumario: | Introduction: PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians. Objective: To add our experience to increase evidence about PRP. Methods: We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP. Results: PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years). Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response. Conclusion: Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma. |
|---|